BioMark Diagnostics to Conduct Validation Studies for its Patented Assays in Patients with Lung Cancer Dr. James Bond of Surrey Memorial Hospital to act as Principal Investigator
BioMark Diagnostics to Conduct Validation Studies (PDF) ———————————————
BioMark Diagnostics to Conduct Validation Studies for its Patented Assays in Patients with Lung CancerDr. James Bond of Surrey Memorial Hospital to act as Principal Investigator
BioMark Diagnostics to Conduct Validation Studies (PDF) ———————————————
BioMark Diagnostics Receives Clearance from Health Canada to Commence Clinical Trial with Patented Non-Invasive, Urine-Based Assay to Measure Response to Treatment for Lung Cancer
Sept 9thBioMark Diagnostics Receives Clearance from Health Canada (PDF) ———————————————
BioMark Diagnostics Announces Progress in Assay Validation for Clinical Sample Analysis
BioMark Diagnostics Announces Progress in Assay Validation for Clinical Sample Analysis_1 (PDF) ———————————————
BioMark Diagnostics Unveils U.S. Strategy
Biomark US Strategy (PDF) ———————————————
BioMark Appoints Dr. Thomas Malcolm to Lead U.S. Operations
BioMark Appoints Dr. Thomas Malcolm to Lead U.S. Operations (PDF) ———————————————
BioMark Diagnostics-Sponsored Project Receives NSERC Engage Grant
BioMark Diagnostics-Sponsored Project Receives NSERC Engage Grant (PDF) ———————————————
BioMark Diagnostics Engages LHA for Investors Relations
BioMark Engages LHA (PDF) ———————————————
Biomark Secures DTC Eligibility
Press Release – BIOMARK SECURES DTC ELIGIBILITY (PDF) ———————————————
BioMark Receives No Objection Letter From Health Canada
BioMark Receives No Objection Letter From Health Canada (PDF) ———————————————
